NanoViricides Inc. (NNVC)

[changes_iv]

I believe we, investors, should take a moment to write an email to our/your Representative/Senator in the U.S. Congress http://www.usa.gov/Contact/US-Congress.shtml
advocating for the Orphan Drug Designation. After all, we the people will benefit in more ways than one from this drug designation.

Follow the format for the email shown in the following link:

http://www.ala.org/aasl/sites/ala.org.aasl/files/content/aboutaasl/aaslcommunity/quicklinks/el/Sample_Letter_to_Elected_Officials.pdf

The benefits are summarized in your post and CDC

http://www.cdc.gov/dengue/epidemiology/local_dengue.html

From Motley Fool:

About Dengue and Dengue Hemorrhagic Fever

Dengue fever, a very old disease, has reemerged in the past 20 years with an expanded geographic distribution of both the viruses and the mosquito vectors, increased epidemic activity, the development of hyper-endemicity (the co-circulation of multiple serotypes), and the emergence of dengue hemorrhagic fever in new geographic regions. In 2013, this mosquito-borne disease is one of the most important tropical infectious diseases globally, with an estimated 400 million cases of dengue fever, over one million cases of dengue hemorrhagic fever, and 50,000-100,000 deaths annually. Dengue virus occurs in four primary serotypes.

A potentially life-threatening dengue disease due to “antibody-dependent enhancement of infection (ADE)” occurs when a patient is infected with a different serotype of dengue virus after the patient’s immune system was “primed” by a previous dengue virus infection. ADE increases the propensity to develop dengue hemorrhagic fever, or dengue shock syndrome, with a high fatality rate. Dengue viruses are carried by mosquitoes that serve as the vectors for the disease. The disease is endemic in many tropical parts of the world, although it is considered an orphan disease in the USA and Europe. (From Clinical Microbiology Reviews).

NanoViricides has also developed an oral drug candidate against influenza. This oral version is also dramatically more effective than TamiFlu in the animals given a lethal influenza virus infection. This oral FluCide may be the very first nanomedicine that is effective when taken by mouth.

In addition, NanoViricides has developed drug candidates against Dengue, HIV/AIDS, Herpes, and Ocular Viral Diseases that have shown strong effectiveness in relevant animal and/or cell culture models.

An orphan designation for our dengue drug candidate, if granted, is expected to help the Company assign a higher priority to its dengue drug program, and undertake rapid development following the influenza drug candidates.